Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com
Patient enrollment has commenced for the randomized phase 3 ULTRA-V trial, which will evaluate the efficacy of a time-limited combination of umbralisib plus ublituximab and venetoclax vs continuous umbralisib/ublituximab in patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia.
Read More
Reduced-Dose Lenalidomide Maintenance Regimen Recommended for Elderly Patients With Myeloma
May 4th 2021Intermediate-fit, elderly patients with newly diagnosed multiple myeloma were found to have similar outcomes with a reduced dose of lenalidomide maintenance therapy after completing 9 cycles of lenalidomide plus dexamethasone compared with standard, continuous dexamethasone.
Read More
Molecular Testing Results Are Critical Amid an Expanding Targeted Therapy Paradigm in Advanced NSCLC
May 3rd 2021Julia K. Rotow, MD, discusses how she approaches molecularly testing in patients with liquid- and tissue-based biopsies, the importance of waiting to initiate immunotherapy until a patient’s molecular testing results are confirmed, and other nuances that she considers when treating patients with advanced non–small cell lung cancer.
Read More
Research Efforts Mount With Immunotherapy in Advanced NSCLC
May 3rd 2021Christopher G. Azzoli, MD, discusses the importance of identifying molecular aberrations prior to starting a patient with advanced non–small cell lung cancer on immunotherapy, ongoing research aimed at furthering the immunotherapy paradigm, and explained why novel biomarkers of response to immunotherapy are needed.
Read More
Tivozanib Approval Adds to the Armamentarium in Relapsed/Refractory Advanced RCC
May 2nd 2021Brian I. Rini, MD, discusses the unique characteristics of tivozanib, how the FDA approval of the VEGF inhibitor is poised to further the advanced RCC paradigm, and the potential future utility of the agent.
Read More
No statistically significant difference in Global Health Status or quality of life was observed with alpelisib vs placebo plus fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer; however, symptom subscales for known adverse effects associated with PI3K inhibitors favored placebo vs alpelisib.
Read More
Observation May Be Preferrable to Surgery in Certain Cases of Desmoid Tumor Fibromatosis
April 29th 2021The local recurrence rate after surgical excision was similar to the rate of progression with active surveillance in patients with extra-abdominal desmoid tumor fibromatosis, suggesting that observation may be sufficient in some cases.
Read More
Atezolizumab/Bevacizumab Combo Sets the Standard for New Doublets in Advanced HCC
April 29th 2021The combination of atezolizumab and bevacizumab has become the frontline standard of care for most patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Read More
Talazoparib Plus Carboplatin Induces Synergistic Activity in Multiple TNBC Cell Lines
April 12th 2021The combination of the PARP inhibitor talazoparib and carboplatin demonstrated synergistic activity in 7 cell lines of triple-negative breast cancer, with greater DNA damage and cell death observed in PARP inhibitor–resistant cell lines and at lower concentrations of talazoparib when combined with carboplatin.
Read More
Seribantumab Induces Tumor Regression in NRG1 Fusion+ GI Cancer Mouse Models
April 11th 2021Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion–positive gastrointestinal cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion–driven cancers.
Read More
Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA
April 7th 2021Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.
Read More
Ongoing Research Is Slated to Optimize Sequencing With Current Standards in Pancreatic Cancer
April 4th 2021Optimizing first- and second-line therapy, understanding the role of maintenance therapy for patients with BRCA-positive disease, and developing improved therapeutic options for elderly patients has become a priority for research in metastatic pancreatic cancer.
Read More
Narsoplimab Inhibits C5b-9 and Thrombus Formation in HSCT/BMT-TMA
April 2nd 2021The addition of narsoplimab to human serum significantly inhibited the formation of C5b-9 and platelet thrombi on human microvascular endothelial cells in 3 patients with acute hematopoietic stem cell transplant – or bone marrow transplant –associated thrombotic microangiopathy.
Read More
Simplified Geriatric Assessment Validated as OS Predictor in Elderly Patients With DLBCL
April 2nd 2021A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.
Read More
OncLive® Takes a Look Back at Most Listened Podcasts of 2020
April 1st 2021Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.
Read More
NCCN Guidelines Include an Abundance of Options Across Multiple Myeloma Paradigm
March 30th 2021The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.
Read More
Immunotherapy Begins to Make Its Way Into Early- and Intermediate-Stage HCC
March 26th 2021Although the combination of atezolizumab and bevacizumab has become the standard frontline treatment for patients with advanced hepatocellular carcinoma, whether immunotherapy could play a role in earlier lines of treatment remains the subject of ongoing research.
Read More
Immunotherapy Makes Waves in Gastroesophageal and Gastric Cancers
March 24th 2021Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.
Read More